We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Virus Identified in Blood Supply

By LabMedica International staff writers
Posted on 30 Sep 2015
Image: The HiSeq 2500 sequencing platform (Photo courtesy of Illumina).
Image: The HiSeq 2500 sequencing platform (Photo courtesy of Illumina).
Transfusion of blood or blood-derived products can save lives and improve health but requires safety measures for preventing bystander transmission of infectious agents.

To investigate the transmission of novel infectious agents by blood transfusion, changes in the virome composition of blood transfusion recipients pre- and post-transfusion has been studied.

An international group of scientists led by those at Columbia University (New York, NY, USA) collected serum samples from four participating blood centers distributed across the USA from July 1974 through June 1980. They performed high-throughput sequencing on blood samples from 46 individuals in the in the Transfusion-Transmitted Viruses Study (TTVS). They also performed high-throughput sequencing on samples from 106 individuals in the Multicenter Hemophilia Cohort Study who received plasma-derived clotting factor concentrates.

Total ribonucleic acid (RNA) extracts were reverse transcribed using a SuperScript III kit (Invitrogen Life Technologies; Carlsbad, CA, USA) with random hexamer primers. After processing, samples with low concentrations were amplified by increasing polymerase chain reaction (PCR) cycle numbers from 9 to 14. All sequencing was done on the Illumina HiSeq 2500 platform (Illumina; San Diego, CA, USA), yielding an average of 150 million reads per sequencing lane.

The team analyzed samples both pre- and post-transfusion and along with a variety of known viruses, they identified a new virus in two individuals. The virus was only present in post-transfusion samples, and additional tests showed that both patients were able to clear the virus. Genetic analysis determined that the novel human virus, human hepegivirus 1 (HHpgV-1) was related to Hepatitis C virus (HCV) and human Pegivirus (HPgV; formerly called GB virus C or Hepatitis G virus). Genomic testing of 70 additional individuals in the TTVS study failed to detect further cases of the virus detected. HHpgV-1 was found in serum samples from two blood transfusion recipients and two hemophilia patients who had received plasma-derived clotting factor concentrates.

Amit Kapoor, PhD, an assistant professor and lead author of the study said, “HHpgV-1 is unique because it shares genetic similarity with both highly pathogenic HCV and the apparently non-pathogenic HPgV. People need to be aware of this new infection in humans. We just don't know how many viruses are transmitted through the blood supply. There are so many viruses out there, and they need to be characterized in order to ensure that transfusions are safe.” The study was published on September 22, 2015, in the journal mBio.

Related Links:

Columbia University 
Invitrogen Life Technologies
Illumina 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Manual Pipetting Aid
Pipette Controllers macro
Gold Member
Neonatal Heel Incision Device
Tenderfoot

Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more